Education
About Us
Working with TipRanks
Follow Us
HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
RESEARCH TOOLSreports
Total Valuation
HemoGenyx Pharmaceuticals Plc has a market cap or net worth of £8.15M. The enterprise value is 5.21B.
Market Cap£8.15M
Enterprise Value5.21B
Share Statistics
HemoGenyx Pharmaceuticals Plc has 4,593,539 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,593,539
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
HemoGenyx Pharmaceuticals Plc’s return on equity (ROE) is -6.26 and return on invested capital (ROIC) is -164.72%.
Return on Equity (ROE)-6.26
Return on Assets (ROA)-1.33
Return on Invested Capital (ROIC)-164.72%
Return on Capital Employed (ROCE)-1.88
Revenue Per Employee0.00
Profits Per Employee-351.20K
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of HemoGenyx Pharmaceuticals Plc is -2.38. HemoGenyx Pharmaceuticals Plc’s PEG ratio is 21.94.
PE Ratio-2.38
PS Ratio0.00
PB Ratio1.59K
Price to Fair Value14.90
Price to FCF-1.56K
Price to Operating Cash Flow-1.79K
PEG Ratio21.94
Income Statement
In the last 12 months, HemoGenyx Pharmaceuticals Plc had revenue of 0.00 and earned -5.62M in profits. Earnings per share was -1.70.
Revenue0.00
Gross Profit-639.28K
Operating Income-5.73M
Pretax Income-5.63M
Net Income-5.62M
EBITDA-4.71M
Earnings Per Share (EPS)-1.70
Cash Flow
In the last 12 months, operating cash flow was -1.78M and capital expenditures -13.28K, giving a free cash flow of -1.80M billion.
Operating Cash Flow-1.78M
Free Cash Flow-1.80M
Free Cash Flow per Share-0.39
Dividends & Yields
HemoGenyx Pharmaceuticals Plc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change-66.86%
50-Day Moving Average178.54
200-Day Moving Average363.67
Relative Strength Index (RSI)45.06
Average Volume (3m)32.63K
Important Dates
HemoGenyx Pharmaceuticals Plc upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.
Last Earnings DateApr 28, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend Date―
Financial Position
HemoGenyx Pharmaceuticals Plc as a current ratio of 0.72, with Debt / Equity ratio of 104.50%
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap0.03
Net Debt to EBITDA-0.52
Interest Coverage Ratio-21.09
Taxes
In the past 12 months, HemoGenyx Pharmaceuticals Plc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
HemoGenyx Pharmaceuticals Plc EV to EBITDA ratio is -3.36, with an EV/FCF ratio of -3.83.
EV to Sales0.00
EV to EBITDA-3.36
EV to Free Cash Flow-3.83
EV to Operating Cash Flow-3.85
Balance Sheet
HemoGenyx Pharmaceuticals Plc has £159.26K in cash and marketable securities with £2.62M in debt, giving a net cash position of £2.46M billion.
Cash & Marketable Securities£159.26K
Total Debt£2.62M
Net Cash£2.46M
Net Cash Per Share£0.54
Tangible Book Value Per Share£0.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for HemoGenyx Pharmaceuticals Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―